Myrsini Ioakeim-Ioannidou, MD
@MyrsiniIoakeim
Postdoc Fellow in Radiation Oncology☢️. @MGHCancerCenter, @harvardmed| Peds/Chordoma/Sarcoma/Breast | Editor @Applied_RadOnc
After our daughter Ceci died at 15 mo of a paraspinal tumor, we’ve been committed to supporting pediatric cancer research. We’re honored this year's Cattle Baron’s Ball will establish Ceci’s Fund through the American Cancer Society. Please share/donate💕 cattlebaronsball.com
Forever grateful to Dr. Shannon MacDonald and the amazing @MGHCancerCenter chordoma team who make this work possible. Let’s keep fighting for our patients!
Very proud of Dr. Myrsini Ioakeim @MyrsiniIoakeim for her very eloquent delivery of prospective data on patterns of relapse for chordoma of the skull base and spine at #PTCOG63 @PTCOG_Official @MassGenBrigham @MGHCancerCenter
Loved chatting with GU radiation oncologist, Dr. Anthony D'Amico. Listen to our far ranging discussion on mentorship, Biden's prostate cancer diagnosis, exercise/wellness, books & more. So much wisdom. Thank you, Dr. D'Amico! Full video link below 👇
Nice summary and discussion. 20% photons was neccessary at HCL and then continued due to comfort level of continuing what worked giving such high doses and exceeding standard tolerance doses to the brainstem with low toxicity. The conformality an additional reason when IMRT…
Excited to share our experience (largest so far) using Boswellia for radiation necrosis with brain mets. ORR 60%, median duration 14 months. Amazing responses and a game changer for patients, I highly recommend you check it out!!! pubmed.ncbi.nlm.nih.gov/39993542/ redjournal.org/article/S0360-…
Nice discussion. I think @SprakerMDPhD is referring to MGH data here – initially was mixed proton/photon due to scheduling (protons only available 4 days/week), also mixed improved skin sparing and conformality using IMRT. With PBS, treatment was 100% protons but that came later.…
The best literature with longest follow up is actually using a mixed plan from the 3D photon days. I've treated with both. Now as a community generalist, I discuss both options and refer to protons if they want. Just not to centers that lie to patients 😀
Incredible #RadOnc Grand Rounds @MGHCancerCenter by Dr. Jona Hattangadi-Gluth @JHGLab on oncofunctional balance in brain tumors—from connectomics to clinical trials. Loved the focus on neuroimaging biomarkers, cognitive-sparing therapies, and the future of precision radiation…
Starting soon: @rachael_hach and I will be moderating the @aapmHQ webinar *How to Start a Lab/Research Program* Speakers: H. Paganetti, H. Whitney, D. Waddington 📅 12 PM ET 💻us06web.zoom.us/webinar/regist…
Congratulation to all awardees🎉🥳, especially our own Helen Shih who we are so lucky to have amongst us. Dr Shih's passion for mentoring and excellence is absolutely amazing, and she does it all with the highest level of diligence & integrity. An inspiration to all of us‼️…
Congratulations to Iris Gibbs, MD, FASTRO; Helen Shih, MD, MS, MPH, FASTRO; & Joachim Yahalom, MD, FASTRO on their 2025 ASTRO Mentorship awards!! They will be recognized at #ASTRO25 in San Francisco. @StanfordRadOnc @MassGeneralNews @MSK_RadOnc ow.ly/A1cB50WlXIa
Excited to add this role to the CF team. The aim is to expand the pipeline of therapies in development for chordoma by allowing us to support and collaborate with more investigators and companies, and drive more research on our own through CF Labs and CRO partners.
🗣️ We're hiring a Director of Preclinical Research! This is an exciting opportunity for an oncology R&D leader to make a tangible impact in the lives of patients in urgent need of new treatment options. More info: chordoma.org/team/careers/
Happy Father’s Day to all the incredible dads of the Mass General Cancer Center community! Today, we’re highlighting Chris Kobos, shown here with his family. Chris was diagnosed with a rare chordoma at the age of 19, and received proton therapy at Mass General Cancer Center. Now…
It was an honor to have @ASTRO_org CEO, Dr. Vivek Kavadi, return to his alma mater @harvardmed & speak on his life/ career trajectory and vision to advance cancer care & our field of radiation oncology! #HROP #BeamOn
Our own Dr. Jason Efstathiou @drjefstathiou from @MGHCancerCenter — a world expert in prostate cancer — tackled one of the toughest but most important topics in today’s plenary: how to handle negative results. The PARTIQoL trial didn’t show a difference in bowel QoL, but it…
Dr. Carlos Vargas @MayoAZRadOnc shared early results from MC1635, a randomized phase 3 trial comparing HF vs UHF breast PMRT with protons or x-rays. ➤ UHF (25 Gy/5 fx) showed fewer AEs and better end-of-treatment QoL ➤ Proton UHF had the largest AE reduction (–11%) ➤ 5-year…
Excellent data shared by Dr. Robert Mutter from @MayoClinic on the MC1631 randomized phase 2 trial comparing CF vs HF proton PMRT. ➤ Similar QoL and satisfaction at 3 years ➤ Supports HF as a viable option, including in patients with reconstruction ➤ Excited to see more from…
Important data shared today by Dr. Homan Mohammadi from @MayoClinicFL on proton reirradiation for head and neck cancer via the Proton Collaborative Group. 📌 Median OS after reRT: 1.6 years 📌 ECOG 1+ and RT interruption linked to worse outcomes 📌 Encouraging toxicity profile…
Truly inspired to hear the clinical chair of RadComp Dr. Shannon MacDonald @ShannonMacDonMD present in the PTCOG-ASTRO plenary session at #PTCOG63. ✅ Accrual complete — 1,238 patients 💙 A landmark trial in breast cancer radiation 👏 Incredible commitment from the team to…
Plenary session at #PTCOG63: @SJFrankMD presented extended OS data from the randomized trial of IMPT vs IMRT in H&N cancer. ✅ Proton therapy improved survival 🔍 Not explained by disease progression or G-tube dependence Looking forward to the full publication of this important…
How is proton therapy used to treat brain tumors? Helen Shih, MD, medical director for the Proton Therapy Centers at Mass General Cancer Center, discusses the effectiveness of proton therapy on brain tumors and why it's important to choose a care team with proven expertise.…
Practice-changing data from Dr. Steven Frank @SJFrankMD at #PTCOG63 on head & neck proton therapy. Level 1 evidence shows improved survival, reduced G-tube dependence, and favorable cost-effectiveness vs IMRT. A new standard is taking shape. @PTCOG_Official @MDAndersonNews
